AnnSurgOncol(2015)22:295–301
DOI10.1245/s10434-014-3898-9
ORIGINAL ARTICLE – PANCREATIC TUMORS
FOLFIRINOX for Locally Advanced Pancreatic
Adenocarcinoma: Results of an AGEO Multicenter Prospective
Observational Cohort
L. Marthey, MD1, A. Sa-Cunha, MD, PhD2, J. F. Blanc, MD, PhD3, M. Gauthier4, A. Cueff4, E. Francois, MD5,
I. Trouilloud, MD6, D. Malka, MD, PhD7, J. B. Bachet, MD, PhD8, R. Coriat, MD, PhD9, E. Terrebonne, MD10,
C. De La Fouchardie`re, MD11, S. Manfredi, MD12, D. Solub, MD13, C. Le´caille, MD14, A. Thirot Bidault, MD1,
F. Carbonnel, MD, PhD1, and J. Taieb, MD, PhD6
1Department of Gastroenterology, Kremlin Biceˆtre Hospital, Assistance publique-Hoˆpitaux de Paris (AP-HP), Paris Sud
University, Le Kremlin Biceˆtre, France; 2Department of Digestive Surgery, Haut-Le´veˆque Hospital, Pessac, France;
3Department of Gastroenterology, Saint-Andre´ Hospital, Bordeaux, France; 4Department of Biostatistics, Anticancer
Center G.F. Leclerc, Dijon, France; 5Department of Oncology, Anticancer Center A. Lacassagne, Nice, France;
6Department of Gastroenterology and Digestive Oncology, HEGP Hospital, Assistance publique-Hoˆpitaux de Paris
(AP-HP),Paris DescartesUniversity,Cancer Research PersonalizedMedicine (CARPEM),Paris, France; 7Department of
Oncology, Institut Gustave Roussy, Villejuif, France; 8Department of Gastroenterology, La Pitie´-Salpe´trie`re Hospital,
Assistance publique-Hoˆpitaux de Paris (AP-HP), Paris, France; 9Department of Gastroenterology, Cochin Hospital,
Assistancepublique-HoˆpitauxdeParis(AP-HP),Paris,France;10DepartmentofGastroenterology,Haut-Le´veˆqueHospital,
Pessac,France;11DepartmentofOncology,AnticancerCenterL.Be´rard,Lyon,France;12DepartmentofGastroenterology,
PontchaillouHospital,Rennes,France;13DepartmentofOncology,L.PasteurHospital,Chartres,France;14Departmentof
Gastroenterology, Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France
ABSTRACT Results. Seventy-seven patients were enrolled. They
Background. First-line treatment with FOLFIRINOX receivedamediannumberoffivecycles(1–30).Grade3–4
significantly increases overall survival (OS) in patients toxicitieswere neutropenia (11 %), nausea(9 %), diarrhea
withmetastaticpancreaticadenocarcinoma(PA)compared (6 %),fatigue(6 %),andanemia(1 %).Grade2–3sensory
withgemcitabine.Theaimofthisobservationalcohortwas neuropathy occurred in 25 % of patients. No toxic death
to evaluate the tolerability and efficacy of this regimen in wasreportedandonly6 %ofpatientshadtostoptreatment
unresectable locally advanced PA (LAPA). becauseoftoxicity.Diseasecontrolratewas84with28 %
Patients and Methods. From February 2010 to February of objective response (Response Evaluation Criteria in
2012, all consecutive patients from 11 French centers Solid Tumors). Seventy-five percent of patients received a
treatedbyFOLFIRINOXforahistologicallyprovenLAPA consolidation therapy: 70 % had radiotherapy and 36 %
were prospectively enrolled. Unresectability was defined underwent a surgical resection, with a curative intent.
independently by each center’s multidisciplinary staff at Within the whole cohort, 1-year OS rate was 77 % (95 %
diagnosis.Absenceofmetastaticdiseasewasconfirmedby CI 65–86) and 1-year progression-free survival rate was
chest-abdomen-pelvis computed tomography scan. FOLF- 59 % (95 % CI 46–70).
IRINOX was delivered every 2 weeks as previously Conclusion. First-line FOLFIRINOX for LAPA seems to
reported until progressive disease, major toxicity, or con- be effective and have a manageable toxicity profile. These
solidation treatment by radiotherapy and/or surgery. promising results will have to be confirmed in a phase III
randomized trial.
(cid:2)SocietyofSurgicalOncology2014
Pancreatic adenocarcinoma (PA) is a frequent and
FirstReceived:27March2014;
PublishedOnline:19July2014 severe disease with an overall 5-year survival rate of
approximately 6 %.1–3 The only way to cure patients is
J.Taieb,MD,PhD
e-mail:julien.taieb@egp.aphp.fr,jtaieb75@gmail.com radical surgical resection, but this is possible in less than
296 L.Martheyetal.
20 % of cases, and only increases the 5-year survival rate Tumor
to 10–27 %4–6 according to the administration of adjuvant
chemotherapy. The following tumor-related information was collected:
LocallyadvancedPA(LAPA)representsabout30 %of dateofdiagnosis,sizeofthetumorinmillimeters,location
pancreatic cancer and its prognosis is half-way between of the tumor (head, body, or tail of the pancreas), absence
that of metastatic and resectable pancreatic cancer. Its or presence of locoregional lymph node involvement on
definition remains controversial because resectability cri- CT scan, and unresectability criteria described as venous
teria differ between centers. Its treatment consists of (superior mesenteric vein, portal vein, portal thrombosis)
palliative chemotherapy, classically with gemcitabine or arterial (superior mesenteric artery, celiac trunk)
similar with metastatic PA treatment. involvement. The presence of a biliary stent was noted.
The ACCORD-11/PRODIGE-4 trial,7 a randomized, Initial evaluation included measurement of carbohydrate
phase III trial, compared the FOLFIRINOX regimen with antigen 19–9 (CA 19–9).
gemcitabine in metastatic PA. It showed a significant
improvement of median overall survival (OS) and pro- Treatment
gression-free survival (PFS), as well as an increase in
response rate. Increased toxicities were also reported with One cycle of FOLFIRINOX consisted of a 2-h intrave-
this three-drug chemotherapy regimen, but the general nous infusion of oxaliplatin (85 mg/m2) followed by a 2-h
tolerability profile was acceptable. However, no cases of intravenous infusion of leucovorin (400 mg/m2) concomi-
LAPA were treated in ACCORD-11/PRODIGE-4 and this tantly with a 90-min intravenous infusion of irinotecan
aggressive treatment has not been evaluated in this cate- (180 mg/m2),followedbyabolus(400 mg/m2)anda46-h
gory of patients. We therefore decided to evaluate the continuous infusion (2,400 mg/m2) of 5-fluorouracil. The
tolerability and efficacy of FOLFIRINOX in patients with FOLFIRINOX regimen was delivered every 2 weeks until
LAPA, inan AGEO (Association des Gastro-Ente´rologues disease progression, patient refusal, unacceptable toxicity,
Oncologues)multicenter,prospective,observationalseries. or consolidation therapy by external radiotherapy and/or
surgery. Primary prophylaxis of neutropenia using granu-
locyte colony-stimulating factor (G-CSF) was initiated at
PATIENTS AND METHODS the physician’s discretion.
Patients Outcomes
Patients with LAPA treated with the FOLFIRINOX Treatment Tolerability The day of the first infusion of
regimen as first-line therapy, between February 2010 and FOLFIRINOX and the number of cycles performed were
February 2012 in 11 French centers, were prospectively recorded.Treatment tolerabilitywasassessed byrecording
enrolled in our database. To be eligible, patients had to be all chemotherapy-related adverse events occurring during
18 years of age or older, have an Eastern Cooperative the study. Nausea and vomiting, diarrhea, fatigue, sensory
Oncology Group performance status (ECOG-PS) score of neuropathy, hand–foot syndrome, mucositis, alopecia,
0, 1, or 2, and a histologically or cytologically proven PA neutropenia, thrombocytopenia, and anemia were
which was non-metastatic but deemed unresectable during evaluated according to the National Cancer Institute
a multidisciplinary meeting with radiological and surgical Common Terminology Criteria for Adverse Events
expertise. Chest-abdomen-pelvis computed tomography V3.0.8 Serious adverse events, including treatment-related
(CT) scans were used to check for the absence of metas- deaths,grade3or4toxicities,toxicwithdrawals,anddose
tases. Unresectability criteria were determined by each reductions associated with adverse events, were noted.
institution’s multidisciplinary staff and were, in all cases,
arterial and/or major venous involvement (at least more Efficacy Disease assessment was performed every
than 180(cid:3) tumor contact, encasement). Previous chemo- 2 months by means of chest-abdomen-pelvis CT scans
therapy or radiotherapy for pancreatic cancer was an andCA19–9monitoring.Radiologicaltumorresponsewas
exclusion criterion. The demographic and clinical charac- defined according to the Response Evaluation Criteria in
teristics of patients were computerized. As FOLFIRINOX Solid Tumors (RECIST)9 on CT scans. Tumor response
is considered a potential standard treatment for non-oper- was classified into four groups: complete response, partial
able pancreatic cancer, with normal bilirubin levels and response, stable disease, or progressive disease.
good performance status, in France, no informed consent Consolidation therapy by surgical resection and/or exter-
was needed for this observational series, as stated by the nalradiotherapywererecorded,togetherwiththeday,typeof
Ethics Committee consulted prior to the start of the work. surgery (duodenopancreatectomy, splenopancreatectomy, or
FOLFIRINOXforLocallyAdvancedPancreaticAdenocarcinoma 297
TABLE1 Characteristicsofpatientsandtumors TABLE2 FOLFIRINOXtoxicities[n(%)]
N=77(%) Grade1 Grade2 Grade3 Grade4
Sex Nauseaandvomiting 21(27) 12(16) 7(9) 0(0)
Male 46(60) Diarrhea 14(18) 17(22) 5(6) 0(0)
Female 31(40) Fatigue 10(13) 12(16) 5(6) 0(0)
Age(years;median[range]) 61[37–79] Sensoryneuropathy 20(26) 16(21) 3(4) 0(0)
ECOG-PS Hand–footsyndrome 1(1) 0(0) 0(0) 0(0)
0 31(40) Mucositis 3(4) 1(1) 0(0) 0(0)
1 45(59) Alopecia 3(4) 6(8) 0(0) 0(0)
2 1(1) Neutropenia 10(13) 8(10) 8(10) 1(1)
Weight(kg;median[range]) 68[42–107] Thrombocytopenia 9(12) 9(12) 0(0) 0(0)
Tumorlocation Anemia 22(29) 4(5) 1(1) 0(0)
Head 50(65) Maximaltoxicity 14(18) 30(39) 19(25) 1(1)
Body 23(30)
Tail 4(5)
causes). Patients without events were censored at the last
Tumorsize(mm;median[range]) 32[25–69]
follow-up date. Survival curves were estimated using the
Nodeinvolvement
Kaplan–Meier method. Median follow-up was calculated
Yes 42(55)
with the reverse Kaplan–Meier method. All analyses were
No 35(45)
performed with a two-sided alpha type 1 error of 5 %.
Vascularinvasion
Arterialinvolvement 50(65)
RESULTS
Venousinvolvement 51(66)
Biliarystent
Characteristics of Patients and Tumors
Yes 36(47)
No 41(53)
Between February 2010 and February 2012, 77 patients
ECOG-PSEasternCooperativeOncologyGroupperformancestatus were enrolled. Their baseline characteristics are summa-
rized in Table 1. Most patients had a good performance
total pancreatectomy), quality of the resection (R0 or R1), status, ECOG-PS 0 or 1. Most tumors were located in the
andthe30-daypostoperativecomplicationsforpatientswho head of the pancreas and 36 patients (47 %) needed a
underwent surgical resection, and the dose of radiation biliary stent before starting chemotherapy. Fifty patients
administered for those who received radiotherapy. Local or had arterial involvement (65 %), concomitantly with a
metastaticrelapseanddeathafterconsolidationtherapywere venous involvement for half of them, and 26 patients
recorded. In the case of progressive disease, if second-line (35 %) had no arterial involvement but a major venous
chemotherapy was administered this was recorded. involvement ([180(cid:3), encasement) which contraindicated
surgical resection.
Statistical Analysis
Tolerability
Patients’ records were prospectively entered into the
database.Quantitativedataweredescribedwiththemedian The median number of cycles administered was five
(range), and qualitative data were described with the per- (range 1–30). No toxic death occurred and only five
centage. There was no statistical hypothesis. A v2 test was patients (6 %) had to stop chemotherapy because of tox-
used to compare qualitative data such as resection rate icity. Treatment was stopped for disease progression in 12
among patients with or without arterial involvement. cases(16 %)andforconsolidationtherapy(radiotherapyor
Objective response was defined as patients with com- surgery) in58 cases (75 %). Grade 3–4 toxicities occurred
pleteresponseorpartialresponse.Diseasecontrolratewas in 20 patients (26 %) and are described in Table 2. Grade
defined as patients with complete response, partial 2–3 sensory neuropathy occurred in 19 patients (25 %). A
response, or stable disease. PFS was defined as the time dose reduction was necessary in 50 cases (65 %). The 5-
elapsedfromthestartofFOLFIRINOXchemotherapyuntil fluorouracil bolus was stopped in 25 patients (32 %)
the date of progression or death (all causes), whichever because of cytopenia, oxaliplatin was stopped in 24
occurredfirst.OSwasdefinedasthetimeelapsedfromthe patients (31 %) after at least six cycles because of neuro-
start of FOLFIRINOX chemotherapy until death (all toxicity,andtheirinotecandosewasreducedin22patients
TABLE3 Efficacyresults 54 Gy (range 45–65 Gy) and 28 (36 %) had a pancreatic
resection.Consolidationtherapy wasdecidedafterthefirst
N(%) 95%CI
tumor evaluation in 74 % of cases (n = 43/58).
Response
Completeresponse 0(0) Survival With a median follow-up of 15 months (range
Partialresponse 22(28) 18–39 3–31), median OS was 22 months, with an upper limit of
Stabledisease 43(56) 44–67 the 95 % CI not reached. The OS rates at 6, 12, and
Progressivedisease 12(16) 7–24 18 months were 96 % (95 % CI 88–99), 77 % (95 % CI
Medianprogression-freesurvival 13months 11–19 65–86),and56 %(95 %CI40–69),respectively.ThePFS
Medianoverallsurvival 22months 17–ND ratesat6,12,and18 monthswere96 %(95 %CI88–99),
59 % (95 % CI 46–70), and 43 % (95 % CI 29–56),
respectively (Fig. 1).
-
- Consolidation Therapy and Outcome Among the 12
patients with a progressive disease despite the
FOLFIRINOX regimen, 11 (92 %) underwent second-line
chemotherapy, all but one by gemcitabine. Among the 28
patients who underwent surgical resection, all were
controlled by FOLFIRINOX and 24 (86 %) were treated
by external radiotherapy before surgery. R0 resection on
pathological examination was described in 25 patients
(89 %).Onlysevenpatients(25 %)hadnodalinvolvement
and four patients (14 %) achieved complete histological
responseonpancreatectomyspecimen.Twenty-fivepatients
(89 %) had a duodenopancreatectomy, two patients (7 %)
had a splenopancreatectomy, and one patient (4 %) had a
total pancreatectomy. Among patients who achieved
surgical resection, 12 (43 %) had initial venous
involvement only and 16 (57 %) had arterial involvement
(p = 0.22).Amongpatientswithvenousinvolvementonly,
44 %(n = 12/27)wereresected;amongthosewitharterial
involvement, 32 % (n = 16/50) were resected. Twelve
(29 %). Prophylactic G-CSF treatment was used in 63 patients (43 %) had postoperative complications. Two
patients (82 %). Only 10 patients (13 %) lost more than patients(7 %)died,bothfrommesentericischemia(oneat
5 % of their total body weight and 11 patients (14 %) day 2 and the other at day 19). Other postoperative
gained more than 5 %. complications were bleeding (n = 3), infection (n = 3),
ascites (n = 2),gastroparesis (n = 2),anastomoticfistulae
Efficacy (n = 1), respiratory dysfunction (n = 1) and lymphorrhea
(n = 1).Altogether,22of28operatedpatients(79 %)were
Survival and tumor response results are summarized in stillaliveattheendofthestudy.Inthesepatientswhowere
Table 3. amenabletosurgery,medianPFSandOSwere22.5 months
(95 % CI 12.9–ND) and 24.9 months (95 % CI 21.1–ND)
Response Partial response rate was observed in 22 fromthedateofthefirstchemotherapycycle,respectively.
patients (28 %) and stable disease in 43 patients (56 %), Median PFS was13.2 months (95 %CI7.4–ND) fromthe
leadingtoadiseasecontrolrateof84 %(95 %CI76–93). date of surgery. Among the 30 patients who underwent
Amongthe60patientswithbaselineCA19.9[37 IU/mL, consolidation therapy by external radiotherapy only, the
38 (63 %) exhibited a significant decrease ([30 %) in mediannumberoffolfirinoxinfusionsreceivedwas6(range
plasmaCA19.9level,and21(35 %)normalizedtheirCA 3–16).Inthesepatients,medianPFSandOSfromthedateof
19.9. first chemotherapy cycle were 11.7 months (95 % CI 6.9–
Moreover, 58 patients (75 %) could undergo post-che- 12.8] and 15.9 months (95 % CI 13.4–ND), respectively.
motherapy consolidation therapy: 54 patients (70 %) Eighteenpatientsrelapsed(60 %),withdistantmetastasesin
received external radiotherapy with a median dose of 14cases(47 %).
ytilibaborP
00.1
57.0
05.0
52.0
00.0
298 L.Martheyetal.
Median PFS = 13 months [1119]
Median OS = 22 months [17ND]
OS
PFS
0 6 12 18 24
N at risk Months
OS 77 73 40 16 2
PFS 77 73 29 12 1
FIG.1 Overall and progression-free survival. Median
PFS=13months (11–19), median OS=22months [17–ND]. OS
overallsurvival,PFSprogression-freesurvival
FOLFIRINOXforLocallyAdvancedPancreaticAdenocarcinoma 299
TABLE4 SummaryofCTorRTCTstudiesinlocallyadvancedpancreaticadenocarcinoma
No.ofpatients Treatment OR(%) MedianPFS(months) MedianOS(months)
Loehreretal.12 74 ArmA=CT 5 6.7 9.2
ArmB=RTCT 6 6 11.1
Huguetetal.13 181 Allpatients – 6.3 11.4
ArmA=CT-RTCT 10.8 15
ArmB=CT 7.4 11.7
Chauffertetal.15 119 – 1year
ArmA=RTCT-CT 14% 8.6
ArmB=CT 32% 13
Conroyetal.18 11/47 Folfirinox 27.3 – 15.7
Hoseinetal.19 14/18 Folfirinox – 1year 1year
83% 100%
Farisetal.20 22 FolfirinoxfollowedbyRTCT 27.3 11.7 –
Gunturuetal.21 16/35 Folfirinox 50 – –
Currentstudy 77 Folfirinox 28 13 22
CTchemotherapy,RTradiotherapy,ORobjectiveresponse,PFSprogression-freesurvival,OSoverallsurvival
DISCUSSION respectively. The present study is based upon the largest
cohort of patients with LAPA treated with FOLFIRINOX.
During the period of our study, from 2010 to 2012, the With28 %ofpatientswithanobjectiveresponse,adisease
standard treatment of borderline or locally advanced pan- control rate of 84 %, and median PFS and OS of 13 and
creatic cancer was gemcitabine-based chemotherapy with 22 months,respectively,thisregimenseemstobeeffective.
or without subsequent consolidation chemoradiother- However,ithastobestatedthatasignificantimpactofpost-
apy.10–14 In this setting, for the whole population starting FOLFIRINOX treatment (e.g. chemoradiotherapy and/or
gemcitabine monotherapy, PFS of 7 months and OS of 9– surgery) could have substantially influenced the outcomes
13 monthswerereported.12,13,15Inthesubgroupofpatients of different patients from different centers along with
who had disease control after 3 months of chemotherapy, impacted the OS. In fact, tumor control and downsizing
consolidation radiochemotherapy resulted in PFS of allowed 75 % of patients to have consolidation therapy,
11 months and OS of 15 months in a large cohort of 181 including pancreatic resection with a curative intent. Sev-
patients.13 These treatments allowed secondary surgical entypercentofpatients received externalradiotherapyand
resection in up to 21 % of patients.16,17 36 % had a pancreatic resection. These results compare
However, the very recent report of the LAP 07 study favorably with those obtained with gemcitabine-based
presented at the American Society of Clinical Oncology chemotherapy10,11orradiochemotherapy12,13andareinline
(ASCO) 2013 annual meeting showed the absence of with the series of patients treated with FOLFIRINOX
benefit of consolidation radiotherapy in LAPA compared mentioned previously.18–21 Table 4 summarizes efficacy
with chemotherapy alone, making consolidation radio- results reported in patients with LAPA treated with che-
therapy debatable today. More intensive chemotherapeutic motherapyor chemoradiotherapy.
regimens thus seem an interesting option in this particular In the metastatic setting, FOLFIRINOX is more toxic
population with limited disease and potential secondary than gemcitabine;7 however, its safety profile seems more
resection possibilities. favorable in our patients with LAPA. One-quarter of our
Few data about FOLFIRINOX in LAPA are currently patients had grade 3–4 toxicities, but with only 6 % of
available.InaphaseIItrial18evaluatingthisschedule,both treatment withdrawal because of tolerability problems. No
metastatic (76 %) and locally advanced (24 %) pancreatic toxicdeathoccurred.Furthermore,althoughstudiesshould
cancer were included. In another work, Hosein et al.19 be compared with caution, the tolerability of FOLFIRI-
recently published a retrospective cohort study of non- NOX was better in our study than in those reported by
metastaticPAtreatedbyFOLFIRINOXincluding23 %of Conroy et al. and Hosein et al.18,19 In these studies, the
resectable tumors. Two other retrospective studies evalu- cumulative rate of grade 3–4 toxicities was higher than
ated 16 and 22 patients treated by FOLFIRINOX for 40 %. These differences could be explained by the better
LAPA20,21andshowedagoodresponserate—27and50 % condition of LAPA patients, but also by the chemotherapy
300 L.Martheyetal.
dose reduction which occurred in 2/3 of our patients and before, and the negative results of the LAP 07 study
the use of prophylactic G-CSF in 82 % of our patients. mentioned previously may favor our intensive chemo-
Fifty-eight patients received consolidation therapy. therapeutic regimen.
Some patients received radiotherapy (n = 30), others had
surgical resection (n = 4), and some received both CONCLUSIONS
(n = 24). Preoperative chemoradiotherapy was adminis-
tered to the vast majority of patients who underwent The FOLFIRINOX regimen seems feasible, with a
surgery. Among patients who underwent a pancreatic manageable toxicity profile, and gives promising efficacy
resection, we recorded two early postoperative deaths, results in LAPA. A randomized trial assessing FOLFIRI-
leadingtoapostoperativemortalityrateof7 %,whichisin NOX versus gemcitabine in this setting is currently
linewiththeUSin-hospitalmortalityratepublishedbyTeh ongoing.
et al.22 in 2009. Both patients had extended pancreatic
resections and received a combined treatment with che- DISCLOSURES L. Marthey, A. Sa-Cunha, J.F. Blanc, M. Gau-
thier,A.Cueff,E.Francois,I.Trouilloud,D.Malka,J.B.Bachet,R.
motherapy and radiotherapy before surgery, and these are
Coriat,E.Terrebonne,C.DeLaFouchardie`re,S.Manfredi,D.Solub,
known to increase the rates of morbidity and mortality of
C. Le´caille, A. Thirot Bidault, F. Carbonnel, and J. Taieb have
pancreatic surgery.16,17,23–25 declarednoconflictsofinterest.
However, this prospective, multicenter study has limi-
tationsasthenumberofpatientswaslimitedanditwasnot
aphaseIItrialbutanobservationalcohort.Moreover,only REFERENCES
good general condition patients with 0–1 performance
statusandnormalbilirubinlevelswereenrolled.However, 1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA
the large homogenous cohort of LAPA patients of the CancerJClin.2012;62:10–29.
2. SantM,AllemaniC,SantaquilaniM,KnijnA,MarchesiF,Ca-
present study seems representative of the general popula-
pocaccia R; EUROCARE Working Group. EUROCARE-4.
tion of patients in this setting. Indeed, the majority of
Survivalofcancerpatientsdiagnosedin1995–1999:resultsand
patientsweremen,hadpancreaticheadcancerwithlymph commentary.EurJCancer.2009;45:931–991.
nodeinvolvement,requiredabiliarystent,andhadatumor 3. Re´seau franc¸ais des registres du cancer Francim. Evolution de
l’incidence et de la mortalite´ par cancer en France de 1978 a`
of 3 cm or more, as reported in previous work on
2000: Institut national de la sante´ et de la recherche me´dicale,
LAPA.12,13,15,17,19 Moreover, the evaluation of non-
Inserm,InVS;2003.
resectability criteria was independently defined by each 4. Katz M, Wang H, Fleming J, et al. Long-term survival after
center at a multidisciplinary staff meeting, as in real-life multidisciplinary management of resected pancreatic adenocar-
cinoma.AnnSurgOncol.2009;16:836–87.
conditions. For this reason, it might be argued that some
5. OettleH,PostS,NeuhausP,etal.Adjuvantchemotherapywith
patients included in this prospective study may have had
gemcitabine versus observation in patients undergoing curative-
borderline rather than unresectable pancreatic cancer, intent resection of pancreatic cancer: a randomized controlled
particularlyamongpatientswithvenousinvolvementonly, trial.JAMA2007;297:267–277.
6. Neoptolemos J, Stocken D, Friess H, et al., for the European
whorepresentedone-thirdofourpopulationstudy.Indeed
Study Group for Pancreatic Cancer. A randomized trial of che-
this may be partly true as the definition of unresectability
moradiotherapy and chemotherapy after resection of pancreatic
wasbased,inourstudy,onreal-lifemultidisciplinarystaff cancer.NEnglJMed.2004;350:1200–10.
decisions and we did not realize a centralized analysis of 7. ConroyT,DesseigneF,YchouM,etal.,fortheGroupeTumeurs
Digestives of Unicancer and the PRODIGE Intergroup. FOLF-
CT scans. However, this also reflects the variability of
IRINOX versus gemcitabine for metastatic pancreatic cancer. N
definitions of borderline and locally advanced in the lit-
EnglJMed.2011;364:1817–1825.
erature (Society of Surgical Oncology/AHPBH; National 8. Cancer Therapy Evaluation Program. Common terminologycri-
Comprehensive Cancer Network; MD Anderson).26 Nev- teria for adverse events, version 3.0. Division of Cancer
TreatmentandDiagnosis,NationalInstitutesofHealth;2003.
ertheless,itisofnotethattheresectionrateamongpatients
9. TherasseP,ArbuckSG,EisenhauerEA,etal.Newguidelinesto
with venous involvement and those with arterial involve-
evaluatetheresponsetotreatmentinsolidtumors.JNatlCancer
mentwassimilar,andthatthesurgicalresectionrateinthe Inst.2000;92:205–216.
subgroup of patients with arterial involvement was high 10. Burris HA, Moore MJ, Andersen J, et al. Improvements in sur-
vivalandclinicalbenefitwithgemcitabineasfirstlinetherapyfor
(32 %). Finally, most patients who achieved surgical
patients with advanced pancreas cancer: a randomized trial. J
resection had also received previous radiotherapy; it is
ClinOncol.1997;15:2403–2413.
therefore difficult to know if the good resection rate 11. Moore MJ,Goldstein D,HammJ,et al.Erlotinib plusgemcita-
observed was due to the FOLFIRINOX regimen, to con- binecomparedwithgemcitabinealoneinpatientswithadvanced
pancreaticcancer:aphaseIIItrialofnationalcancerinstituteof
solidation radiotherapy, or both. However, our efficacy
CanadaClinicalTrialsGroup.JClinOncol.2007;25:1960–1966.
results compare favorably with previous results of che-
12. LoehrerP,FengY,CardenesH,etal.Gemcitabinealoneversus
motherapy followed by radiotherapy,13 as mentioned gemcitabine plus radiotherapy in patients with locally advanced
FOLFIRINOXforLocallyAdvancedPancreaticAdenocarcinoma 301
pancreaticcancer:anEasternCooperativeOncologyGrouptrial. resectable locally advanced pancreatic adenocarcinoma. BMC
JClinOncol.2011;29:4105–4112 Cancer.2012;12:199.
13. Huguet F, Andre T, Hammel P, et al. Impact of chemoradio- 20. FarisJ,BlaszkowskyL,McDermottS,etal.Folfirinoxinlocally
therapy after disease control with chemotherapy in locally advancedpancreaticcancer:theMassachusettsGeneralHospital
advancedpancreaticadenocarcinomainGERCORphaseIIetIII CancerCenterexperience.Oncologist.2013;18:543–548.
studies.JClinOncol.2007;25:3:326–331. 21. Gunturu KS, Yao X, Cong X, Thumar JR, Hochster HS, Stein
14. HuguetF,GirardN,GuercheCS,HennequinC,MornexF,Azria SM, et al. Folfirinox for locally advanced and metastatic pan-
D. Chemoradiotherapy in the management of locally advanced creaticcancer:singleinstitutionretrospective reviewofefficacy
pancreatic carcinoma: a qualitative systematic review. J Clin andtoxicity.MedOncol.2013;30:361.
Oncol.2009;27:2269–77. 22. TehSH,DiggsB,DeveneyC,SheppardB.Patientandhospital
15. Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial com- characteristics on the variance of perioperative outcomes for
paringintensiveinductionchemoradiotherapy(60Gy,infusional pancreatic resection in the United States: a plea for outcome-
5-FU and intermittent cisplatin) followed by maintenance gem- based and not volume-based referral guidelines. Arch Surg.
citabine with gemcitabine alone for locally advanced 2009;144:713–721.
unresectablepancreaticcancer.AnnOncol.2008;19:1592–1599. 23. Crane CH, Abbruzzese JL, Evans DB, et al. Is the therapeutic
16. Ammori J, Colletti L, Zalupski M, et al. Surgical resection fol- indexbetterwithgemcitabine-basedchemoradiationthanwith5-
lowingradiationtherapywithconcurrentgemcitabineinpatients fluorouracil-basedchemoradiationinlocallyadvancedpancreatic
with previously unresectable adenocarcinoma of the pancreas. J cancer?IntJRadiatOncolBiolPhys.2002;52:1293–1302.
GastrointestSurg.2003;7:766–72. 24. Hartwig W, Hackert T, Hinz U, Hassenpflug M, Strobel O,
17. Sa Cunha A, Rault A, Laurent C, et al. Surgical resection after Bu¨chler MW, et al. Multivisceral resection for pancreatic
radiochemotherapyinpatientswithunresectableadenocarcinoma malignancies: risk-analysis and long term outcomes. Ann Surg.
ofthepancreas.JAmCollSurg.2005;201:359–365. 2009;250:81–87.
18. ConroyT,PaillotB,FrancoisE,etal.Irinotecanplusoxaliplatin 25. Gillen S, Schuster T, Meyer Zum Bu¨schenfelde C, Friess H,
and leucovorin-modulated fluorouracil in advanced pancreatic KleeffJ.Preoperative/neoadjuvanttherapyinpancreaticcancer:a
cancer. A Groupe Tumeurs Digestives of the Federation Natio- systematic review and meta-analysis of response and resection
naledesCentresdeLutteContreleCancerstudy.JClinOncol. percentages.PLoSMed.2010;7:e1000267.
2005;23:1228–1236. 26. EvansDB, Erickson BA,Ritch P.Borderline resectable pancre-
19. HoseinPJ,MacintyreJ,KawamuraC,etal.Aretrospectivestudy atic cancer: definitions and the importance of multimodality
of neoadjuvant FOLFIRINOX in unresectable or borderline- therapy.AnnSurgOncol.2010;17(11):2803–5.
